Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity

References

• Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Exp. Opin. Drug Saf.5(6), 791–809 (2006).
   PubMed Web of Science ®Google Scholar
• Myers C, Bonow R, Palmeri S et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol.10(1 Suppl. 1), 53–55 (1983).
   PubMed Web of Science ®Google Scholar
• Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol.131(5), 561–578 (2005).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res.51(18), 4903–4908 (1991).
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem. Pharmacol.50(7), 953–958 (1995).
   PubMed Web of Science ®Google Scholar
• Gorbsky GJ. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res.54(4), 1042–1048 (1994).
   PubMedGoogle Scholar
• Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol.51(7), 879–886 (1996).
   PubMed Web of Science ®Google Scholar
• Hellmann K, Burrage K. Control of malignant metastases by ICRF l59. Nature224(5216), 273–275 (1969).
   PubMed Web of Science ®Google Scholar
• Salsbury AJ, Burrage K, Hellmann K. Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic. Br. Med. J.4(5731), 344–346 (1970).
   PubMed Web of Science ®Google Scholar
• Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. Br. Med. J.1(5800), 597–601 (1972).
   PubMed Web of Science ®Google Scholar
• Popelová O, Sterba M, Simunek T et al. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J. Pharmacol. Exp. Ther.326(1), 259–269 (2008).
   PubMed Web of Science ®Google Scholar
• Bruynzeel AM, Niessen HW, Bronzwaer JG et al. The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a Phase II study. Br. J. Cancer97(8), 1084–1089 (2007).
   PubMed Web of Science ®Google Scholar
• Herman E, Ardalan B, Bier C, Waravdekar V, Krop S. Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat. Rep.63(1), 89–92 (1979).
   PubMedGoogle Scholar
• Herman EH, Ferrans VJ. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis (3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res.41(9 Pt 1), 3436–3440 (1981).
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem.5(1), 1–28 (1998).
   PubMed Web of Science ®Google Scholar
• Hasinoff BB. Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase. Chirality6(3), 213–215 (1994).
   PubMedGoogle Scholar
• Hasinoff BB, Kala SV. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [ (+)-1,2-bis (3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925. Agents Actions39(1–2), 72–81 (1993).
   PubMedGoogle Scholar
• Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol.26(22), 3777–3784 (2008).
   PubMed Web of Science ®Google Scholar
• Holcenberg JS, Tutsch KD, Earhart RH et al. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat. Rep.70(6), 703–709 (1986).
   PubMedGoogle Scholar
• Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs56(3), 385–403 (1998).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Gorowski E, Davila E et al. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Invest. New Drugs5(2), 187–198 (1987).
   PubMed Web of Science ®Google Scholar
• Earhart RH, Tutsch KD, Koeller JM et al. Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients. Cancer Res.42(12), 5255–5261 (1982).
   PubMed Web of Science ®Google Scholar
• Hochster H, Liebes L, Wadler S et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl Cancer Inst.84(22), 1725–1730 (1992).
   PubMedGoogle Scholar
• Liesmann J, Belt R, Haas C, Hoogstraten B. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy. Cancer47(8), 1959–1962 (1981).
   PubMedGoogle Scholar
• Von Hoff DD, Howser D, Lewis BJ, Holcenberg J, Weiss RB, Young RC. Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat. Rep.65(3–4), 249–252 (1981).
   PubMedGoogle Scholar
• Koeller JM, Earhart RH, Davis HL. Phase I trial of ICRF-187 by 48-hour continuous infusion. Cancer Treat. Rep.65(5–6), 459–463 (1981).
   PubMedGoogle Scholar
• Natale RB, Wheeler RH, Liepman MK, Sauder A, Bricker L. Phase II trial of ICRF-187 in non-small-cell lung cancer. Cancer Treat. Rep.67(3), 311–313 (1983).
   PubMedGoogle Scholar
• Brubaker LH, Vogel CL, Einhorn LH, Birch R. Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial. Cancer Treat. Rep.70(7), 915–916 (1986).
   PubMedGoogle Scholar
• Wheeler RH, Bricker LJ, Natale RB, Baker SR. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck. Cancer Treat. Rep.68(2), 427–428 (1984).
   PubMedGoogle Scholar
• Chachoua A, Green M, Wernz J, Muggia F. Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi’s sarcoma (AIDS-KS). Invest. New Drugs17(4), 327–331 (1989).
   Google Scholar
• Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol.10(1), 117–127 (1992).
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol.15(4), 1318–1332 (1997).
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol.15(4), 1333–1340 (1997).
   PubMed Web of Science ®Google Scholar
• Venturini M, Michelotti A, Del Mastro L et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J. Clin. Oncol.14(12), 3112–3120 (1996).
   PubMed Web of Science ®Google Scholar
• Marty M, Espié M, Llombart A, Monnier A, Rapoport BL, Stahalova V; Dexrazoxane Study Group. Multicenter randomized Phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann. Oncol.17(4), 614–622 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez M, Vici P, Di Lauro K et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J. Clin. Oncol.16(1), 86–92 (1998).
   PubMed Web of Science ®Google Scholar
• Wexler LH, Andrich MP, Venzon D et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol.14(2), 362–372 (1996).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med.351(2), 145–153 (2004).
   PubMed Web of Science ®Google Scholar
• Feldman JE, Jones SE, Weisberg SR et al. Advanced small cell lung cancer treated with CAV (cyclophosphamide, adriamycin, vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard). Proc. Am. Soc. Clin. Oncol.11, 296 (Abstract 993) (1992).
   Google Scholar
• Moghrabi A, Levy DE, Asselin B et al. Results of the Dana–Farber Cancer Institute ALL Consortium Protocol 95–01 for children with acute lymphoblastic leukemia. Blood109(3), 896–904 (2007).
   PubMed Web of Science ®Google Scholar
• Kolaric K, Bradamante V, Cervek J et al. A Phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology52(3), 251–255 (1995).
   PubMed Web of Science ®Google Scholar
• Bu’Lock FA, Gabriel HM, Oakhill A, Mott MG, Martin RP. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br. Heart J.70(2), 185–188 (1993).
   PubMedGoogle Scholar
• van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev.2, CD003917 (2008).
   Google Scholar
• Seymour L, Bramwell V, Moran LA; The Provincial Systemic Treatment Disease Site Group. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev. Control3(2), 145–159 (1999).
   PubMedGoogle Scholar
• Bates M, Lieu D, Zagari M, Spiers A, Williamson T. A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Clin. Ther.19(1), 167–184 (1997).
   PubMed Web of Science ®Google Scholar
• Tonkin K, Bates M, Lieu D, Arundell E, Williamson T, Zagari M. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. Can. J. Oncol.6(2), 458–473 (1996).
   PubMedGoogle Scholar
• Tebbi CK, London WB, Friedman D et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J. Clin. Oncol.25(5), 493–500 (2007).
   PubMed Web of Science ®Google Scholar
• Barry EV, Vrooman LM, Dahlberg SE et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J. Clin. Oncol.26(7), 1106–1111 (2008).
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Langer SW, Buter J et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann. Oncol.18(3), 546–550 (2007).
   PubMed Web of Science ®Google Scholar
• Steiner R, Hellman K. Cytoprotection by dexrazoxane. Presented at: 19th International Congress on Anti Cancer Treatment. Paris, France, 5–8 February 2008.
   Google Scholar